Blood test may help cancer patients avoid nerve damage from chemo
NCT ID NCT03987555
First seen Jan 04, 2026 · Last updated Apr 28, 2026 · Updated 23 times
Summary
This study looks at whether doctors can consistently measure the amount of paclitaxel (a chemotherapy drug) in the blood of cancer patients. The goal is to see if this information can help adjust doses to kill cancer while reducing nerve damage, a common side effect. About 22 adults with various solid tumors (like breast, lung, or ovarian cancer) will participate. The study is currently suspended.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for STAGE IV LUNG CANCER AJCC V8 are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Wake Forest Baptist Comprehensive Cancer Center
Winston-Salem, North Carolina, 27157, United States
Conditions
Explore the condition pages connected to this study.